Roche halts Avastin lymphoma trial on negative risk:benefit ratio
This article was originally published in Scrip
Executive Summary
Roche has halted a Phase III trial looking at the efficacy of Avastin (bevacizumab) when added to Roche/Biogen Idec's MabThera (rituximab) plus CHOP (cyclophosphamide plus doxorubicin plus vincristine plus prednisone) chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL).